AYTU BIOPHARMA, INC Unamortized Debt Issuance Expense
AYTU BIOPHARMA, INC (AYTU) had Unamortized Debt Issuance Expense of $253.00 thousand as of 2015-12-31, per its 10-Q filed 2016-02-11.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2017-08-31
- 2015-12-31: Unamortized Debt Issuance Expense $253.00K.
- 2015-09-30: Unamortized Debt Issuance Expense $350.00K.
- 2015-08-31: Unamortized Debt Issuance Expense $401.00K.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2015-12-31 | $253.00K 10-Q · filed 2016-02-11 |
| 2015-09-30 | $350.00K 10-Q · filed 2015-11-06 |
| 2015-08-31 | $401.00K 10-K · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |